We considered that timolol may have an effect in wound healing promotion in patients who undergo AFCO2 resurfacing. Our study aimed to investigate the efficacy and safety of 0.5% topical timolol malea
Conditions
Interventions
timolol,
which is non-
selective beta blocker,
could promote the keratinocyte migration rate via mitogen-
activated protein kinase signaling pathway and accelerate the wound healing rate.
Active Comparator Drug
0.5% timolol maleate
Sponsors
none
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The participants aged 18-50 years old with atrophic area scars for at least three months
Exclusion criteria
Exclusion criteria: 1) pregnant/lactating female, 2) history of isotretinoin use within previous 3 months before enrollment, 3) history of cosmetic procedures including botulinum toxin, filler, collagen, lasers within the preceding 3 months, 4) history of photosensitivity or skin cancer, 5) history of psoriasis, hypertension, or asthma, 6) allergy to anesthetic agents, or timolol solution, 7) active dermatitis or herpes infection (within previous 2 weeks), 8) Fitzpatrick skin type V – VI, 9) current or history of previous use within one month of anticoagulative drugs or NSAIDs use or previous use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| corneometry and TEWL - biophysical measurements by Cutometer dual MPA 580 | — |
Secondary
| Measure | Time frame |
|---|---|
| edema, erythema, and crusting score - 4-point grading scale by dermatologists | — |
Countries
Thailand
Contacts
Public ContactChanat Kumtornrut
Chulalongkorn University
Outcome results
None listed